Immunome Inc (NASDAQ: IMNM) on Tuesday, plunged -10.29% from the previous trading day, before settling in for the closing price of $8.50. Within the past 52 weeks, IMNM’s price has moved between $5.15 and $16.81.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -7.10%. The company achieved an average annual earnings per share of 48.00%. With a float of $76.85 million, this company’s outstanding shares have now reached $87.01 million.
Let’s determine the extent of company efficiency that accounts for 118 employees. In terms of profitability, gross margin is 83.07%, operating margin of -3382.37%, and the pretax margin is -3240.38%.
Immunome Inc (IMNM) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Immunome Inc is 11.68%, while institutional ownership is 63.40%. The most recent insider transaction that took place on Mar 25 ’25, was worth 60,684. In this transaction Director of this company bought 7,800 shares at a rate of $7.78, taking the stock ownership to the 31,415 shares. Before that another transaction happened on Mar 26 ’25, when Company’s President and CEO bought 137,100 for $7.29, making the entire transaction worth $999,459. This insider now owns 806,736 shares in total.
Immunome Inc (IMNM) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 48.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.19% during the next five years compared to -38.15% drop over the previous five years of trading.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Immunome Inc (IMNM) is currently performing well based on its current performance indicators. A quick ratio of 4.08 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 73.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.18, a number that is poised to hit -0.63 in the next quarter and is forecasted to reach -2.79 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Looking closely at Immunome Inc (NASDAQ: IMNM), its last 5-days average volume was 0.88 million, which is a drop from its year-to-date volume of 1.08 million. As of the previous 9 days, the stock’s Stochastic %D was 37.79%. Additionally, its Average True Range was 0.59.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 26.70%, which indicates a significant decrease from 30.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.53% in the past 14 days, which was lower than the 76.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.02, while its 200-day Moving Average is $11.39. However, in the short run, Immunome Inc’s stock first resistance to watch stands at $8.24. Second resistance stands at $8.85. The third major resistance level sits at $9.19. If the price goes on to break the first support level at $7.28, it is likely to go to the next support level at $6.94. Should the price break the second support level, the third support level stands at $6.33.
Immunome Inc (NASDAQ: IMNM) Key Stats
Market capitalization of the company is 663.46 million based on 87,012K outstanding shares. Right now, sales total 9,040 K and income totals -292,960 K. The company made 2,740 K in profit during its latest quarter, and -80,250 K in sales during its previous quarter.
